Top Markets
Coin of the day
NuGenerex Immuno-Oncology, Inc. NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc.

NUGX
Rank in Stocks #41797
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
Share Price
$0.0001
Last synced: 2023-05-22
Market Cap
$10.03K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade NuGenerex Immuno-Oncology, Inc. (NUGX)

Category

P/B ratio for NuGenerex Immuno-Oncology, Inc. (NUGX)
P/B ratio as of 2026 TTM: 0
According to NuGenerex Immuno-Oncology, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for NuGenerex Immuno-Oncology, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR